| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hilal Seven, Medine Giynaş Ayhan, Ayşe Kürkcü, Süleyman Özbek, İbrahim Ere. Aripiprazole-induced Asymptomatic Hypertension: A Case Report. Psychopharmacology bulletin. vol 47. issue 2. 2019-05-30. PMID:28626272. |
in this case report, however, we present the case of a medically healthy patient with schizophrenia who developed hypertension (ht) after the initiation of aripiprazole. |
2019-05-30 |
2023-08-13 |
Not clear |
| Bunta Yoshimura, Kojiro Sato, Shinji Sakamoto, Masaru Tsukahara, Yusaku Yoshimura, Ryuhei S. Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. Psychopharmacology. vol 236. issue 2. 2019-04-25. PMID:30443794. |
incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. |
2019-04-25 |
2023-08-13 |
Not clear |
| Shin Ono, Takuro Sugai, Yutaro Suzuki, Manabu Yamazaki, Kazutaka Shimoda, Takao Mori, Yuji Ozeki, Hiroshi Matsuda, Norio Sugawara, Norio Yasui-Furukori, Kurefu Okamoto, Toyoaki Sagae, Toshiyuki Somey. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. BMC psychiatry. vol 18. issue 1. 2019-04-19. PMID:29879941. |
the aim of the present study was to compare the levels of high-density lipoprotein (hdl)-cholesterol in japanese schizophrenia patients medicated with olanzapine, risperidone, or aripiprazole monotherapy. |
2019-04-19 |
2023-08-13 |
Not clear |
| Catherine Weiss, Emmanuelle Weiller, Ross A Baker, Ruth A Duffy, Keva K Gwin, Peter Zhang, Robert D McQuad. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. International clinical psychopharmacology. vol 33. issue 5. 2019-04-18. PMID:29878915. |
the effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. |
2019-04-18 |
2023-08-13 |
Not clear |
| Catherine Weiss, Emmanuelle Weiller, Ross A Baker, Ruth A Duffy, Keva K Gwin, Peter Zhang, Robert D McQuad. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. International clinical psychopharmacology. vol 33. issue 5. 2019-04-18. PMID:29878915. |
the aim of this analysis was to explore the effects of brexpiprazole and aripiprazole on body weight when used as monotherapy to treat schizophrenia and as adjunctive treatment to antidepressant treatment (adt) for major depressive disorder (mdd) in short-term (4/6 weeks) and long-term (≤52 weeks) studies. |
2019-04-18 |
2023-08-13 |
Not clear |
| Catherine Weiss, Emmanuelle Weiller, Ross A Baker, Ruth A Duffy, Keva K Gwin, Peter Zhang, Robert D McQuad. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. International clinical psychopharmacology. vol 33. issue 5. 2019-04-18. PMID:29878915. |
body weight data were obtained from the clinical studies of each drug (brexpiprazole and aripiprazole), in schizophrenia and adjunctive treatment of mdd. |
2019-04-18 |
2023-08-13 |
Not clear |
| Catherine Weiss, Emmanuelle Weiller, Ross A Baker, Ruth A Duffy, Keva K Gwin, Peter Zhang, Robert D McQuad. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. International clinical psychopharmacology. vol 33. issue 5. 2019-04-18. PMID:29878915. |
in short-term schizophrenia studies, the mean weight increase was 1.2 kg for brexpiprazole and 0.6 kg for aripiprazole. |
2019-04-18 |
2023-08-13 |
Not clear |
| Catherine Weiss, Emmanuelle Weiller, Ross A Baker, Ruth A Duffy, Keva K Gwin, Peter Zhang, Robert D McQuad. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. International clinical psychopharmacology. vol 33. issue 5. 2019-04-18. PMID:29878915. |
in the long-term schizophrenia studies, at week 52, the mean weight increase was 2.1 kg for brexpiprazole and 3.0 kg for aripiprazole. |
2019-04-18 |
2023-08-13 |
Not clear |
| Manabu Takaki, Masafumi Kodama, Yutaka Mizuki, Hiroki Kawai, Bunta Yoshimura, Makiko Kishimoto, Shinji Sakamoto, Yuko Okahisa, Norihito Yamad. Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 5. 2019-04-08. PMID:29571966. |
aripiprazole), are administered for treatment of schizophrenia. |
2019-04-08 |
2023-08-13 |
rat |
| Paolo Girardi, Antonio Del Casale, Chiara Rapinesi, Georgios D Kotzalidis, Francesca Splendori, Claudio Verzura, Giada Trovini, Serena Sorice, Dario Carrus, Iginia Mancinelli, Anna Comparelli, Sergio De Filippis, Antonio Francomano, Andrea Ballerini, Andrea Marcellusi, Francesco S Mennini, Giuseppe Ducci, Gabriele Sani, Maurizio Pompili, Roberto Brugnol. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Human psychopharmacology. vol 33. issue 3. 2019-04-03. PMID:29766576. |
predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. |
2019-04-03 |
2023-08-13 |
Not clear |
| Paolo Girardi, Antonio Del Casale, Chiara Rapinesi, Georgios D Kotzalidis, Francesca Splendori, Claudio Verzura, Giada Trovini, Serena Sorice, Dario Carrus, Iginia Mancinelli, Anna Comparelli, Sergio De Filippis, Antonio Francomano, Andrea Ballerini, Andrea Marcellusi, Francesco S Mennini, Giuseppe Ducci, Gabriele Sani, Maurizio Pompili, Roberto Brugnol. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Human psychopharmacology. vol 33. issue 3. 2019-04-03. PMID:29766576. |
paliperidone palmitate (pal) and aripiprazole monohydrate (ari) lai treatments were associated with improvements in global functioning in patients with schizophrenia. |
2019-04-03 |
2023-08-13 |
Not clear |
| Arun Singh, Srihari Gopal, Edward Kim, Maju Mathews, Jennifer Kern-Sliwa, Ibrahim Turkoz, Annette Wooller, Jesse Berli. Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International clinical psychopharmacology. vol 33. issue 4. 2019-03-27. PMID:29494348. |
methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. |
2019-03-27 |
2023-08-13 |
Not clear |
| Arun Singh, Srihari Gopal, Edward Kim, Maju Mathews, Jennifer Kern-Sliwa, Ibrahim Turkoz, Annette Wooller, Jesse Berli. Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International clinical psychopharmacology. vol 33. issue 4. 2019-03-27. PMID:29494348. |
the authors concluded that the results may suggest relative advantages for aripiprazole once monthly over paliperidone palmitate once monthly in the short-term treatment of schizophrenia. |
2019-03-27 |
2023-08-13 |
Not clear |
| G Gozlan, L Lecardeur, A-S Monfort, M Doz, I Ortiz, P Larroumets, A Lafum. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France]. L'Encephale. vol 44. issue 6. 2019-03-25. PMID:30482480. |
[cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in france]. |
2019-03-25 |
2023-08-13 |
Not clear |
| G Gozlan, L Lecardeur, A-S Monfort, M Doz, I Ortiz, P Larroumets, A Lafum. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France]. L'Encephale. vol 44. issue 6. 2019-03-25. PMID:30482480. |
the aim of the study was to estimate the cost-effectiveness ratio of aripiprazole once-monthly compared to once-monthly injectable paliperidone palmitate in the treatment of schizophrenia in france on the basis of results and data from the qualify study. |
2019-03-25 |
2023-08-13 |
Not clear |
| Luis San, Gemma Estrada, Natalia Oudovenko, Francisco Montañés, Natalia Dobrovolskaya, Olga Bukhanovskaya, Mikhail Popov, Eduard Viet. PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 6. 2019-03-22. PMID:29724638. |
placid study: a randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. |
2019-03-22 |
2023-08-13 |
Not clear |
| Luis San, Gemma Estrada, Natalia Oudovenko, Francisco Montañés, Natalia Dobrovolskaya, Olga Bukhanovskaya, Mikhail Popov, Eduard Viet. PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 6. 2019-03-22. PMID:29724638. |
the aim of the study was to investigate the efficacy and safety of inhaled loxapine compared with the intramuscular (im) antipsychotic aripiprazole in acutely agitated patients with schizophrenia or bipolar i disorder. |
2019-03-22 |
2023-08-13 |
Not clear |
| Luis San, Gemma Estrada, Natalia Oudovenko, Francisco Montañés, Natalia Dobrovolskaya, Olga Bukhanovskaya, Mikhail Popov, Eduard Viet. PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 6. 2019-03-22. PMID:29724638. |
patients (aged 18-65 years) diagnosed with schizophrenia or bipolar i disorder experiencing acute agitation (clinical global impression [cgi]-severity score ≥ 4) while hospitalized or attending an emergency room were randomized to receive up to two doses of inhaled loxapine 9.1 mg or im aripiprazole 9.75 mg (≥ 2 h between doses) during the 24-h study period. |
2019-03-22 |
2023-08-13 |
Not clear |
| Luis San, Gemma Estrada, Natalia Oudovenko, Francisco Montañés, Natalia Dobrovolskaya, Olga Bukhanovskaya, Mikhail Popov, Eduard Viet. PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 6. 2019-03-22. PMID:29724638. |
inhaled loxapine reduced agitation faster than im aripiprazole, supporting its use as a first-line option for managing acute agitation in patients with schizophrenia or bipolar disorder. |
2019-03-22 |
2023-08-13 |
Not clear |
| Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Ayako Mikami, Hideo Matsumoto, Katsunaka Mikam. Reduced insomnia following short-term administration of suvorexant during aripiprazole once-monthly treatment in a patient with schizophrenia. Asian journal of psychiatry. vol 28. 2019-02-28. PMID:28784378. |
reduced insomnia following short-term administration of suvorexant during aripiprazole once-monthly treatment in a patient with schizophrenia. |
2019-02-28 |
2023-08-13 |
Not clear |